Search
lenacapavir (Sunlenca)
Indications:
- multi-drug resistant HIV1 infection
- combined with other antiretroviral agents
- HIV1 pre-exposure prophylaxis (investigational) [2,3]*
* incidence of HIV1 infection in cisgender women 0/100 person-years [3,4]
Dosage:
- given both orally & by subcutaneous injection every 6 months
Mechanism of action:
- HIV1 capsid inhibitor
Notes:
- estimated cost $42,250 in the first year of treatment
- therafter $39,000 annually in the subsequent years
Interactions
drug adverse effects of antiretroviral agents
General
antiretroviral agent
References
- Hick L
FDA Approves First-in-Class Drug for HIV
Medscape. December 22, 2022
https://www.medscape.com/viewarticle/986049
- NEJM Journal Watch. July 30, 2024
2024 International AIDS Conference (results of the PURPOSE-1 study)
- Bekker L-G et al.
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women.
N Engl J Med 2024 Jul 24; [e-pub].
PMID: 39046157
https://www.nejm.org/doi/10.1056/NEJMoa2407001
- Walensky RP, Baden LR.
The real PURPOSE of PrEP - effectiveness, not efficacy.
N Engl J Med 2024 Jul 24; [e-pub].
PMID: 39046168
https://www.nejm.org/doi/10.1056/NEJMe2408591
- Yamey G, Machingaidze S.
Lenacapavir: a giant step forward in HIV prevention-but a missed opportunity
for achieving equity and access.
BMJ. 2024 Oct 14;387:q2254. doi: 10.1136/bmj.q2254.
PMID: 39401824